Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of (177)Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer

(177)Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane antigen (PSMA), enabling targeted β-irradiation of prostate cancer. We have previously reported favorable activity with low toxicity in a prospective phase II trial involving 30 men with metastatic castration-resista...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Nucl Med
Principais autores: Violet, John, Sandhu, Shahneen, Iravani, Amir, Ferdinandus, Justin, Thang, Sue-Ping, Kong, Grace, Kumar, Aravind Ravi, Akhurst, Tim, Pattison, David, Beaulieu, Alexis, Mooi, Jennifer, Tran, Ben, Guo, Christina, Kalff, Victor, Murphy, Declan G, Jackson, Price, Eu, Peter, Scalzo, Mark, Williams, Scott, Hicks, Rodney J., Hofman, Michael S.
Formato: Artigo
Idioma:Inglês
Publicado em: Society of Nuclear Medicine 2020
Assuntos:
Theranostics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7262220/
https://ncbi.nlm.nih.gov/pubmed/31732676
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.119.236414
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados